Despite the availability of many effective medications and management options, many people with type 2 diabetes have low adherence to treatments which can lead to adverse health outcomes. We aimed to better understand the challenges related to type 2 diabetes medication adherence through interviews with people with type 2 diabetes with varying degrees of medication adherence. Phone interviews were conducted in English or French, lasted 45 minutes, and followed a semi-structured discussion guide informed by the Theoretical Domains Framework (TDF) . Eligibility criteria included being diagnosed with type 2 diabetes for at least 2 years and current use of diabetes medication (s) . A total of 30 people with type 2 diabetes were interviewed, with representation across Canada, by gender (14F/16M) , years since diagnosis (12.9±7.9) , types of medication and regimen (n=15 on polypharmacy) , and medication adherence levels (n=for each of the low/medium/high adherence groups) . Themes related to medication adherence identified from interviews mapped to 12 of the 14 TDF domains, with the Knowledge and Skills domain being the exceptions. Compared to people with type 2 diabetes categorized to the high adherence group, those categorized to the low adherence group doubted the appropriateness of their medications; reported less access to healthcare providers; tended not to use organizational tools to help with taking medication; and discussed financial barriers to accessing their medications. In contrast to those in the low adherence category, we found that highly adherent people with type 2 diabetes often viewed taking their medication as an emotionally neutral task. To validate these findings, additional quantitative research is underway to help support people with type 2 diabetes to overcome the psychological and tangible barriers to adherence and impact the perception of taking medication as a task without emotional connotations and stigma.

Disclosure

M. Vallis: Advisory Panel; Bausch Health, Canada, Novo Nordisk Canada Inc. Consultant; Abbott Diabetes, LifeScan. Speaker's Bureau; AbbVie Inc., Bausch Health, Canada, LifeScan, Novo Nordisk, Novo Nordisk A/S. S. Jin: Advisory Panel; Novo Nordisk Canada Inc. Consultant; Abbott Diabetes, Boehringer Ingelheim International GmbH, Dexcom, Inc., HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., MDBriefcase. Research Support; Novo Nordisk Canada Inc. Speaker's Bureau; Abbott Diabetes, Boehringer Ingelheim International GmbH, Eisai Inc., EOCI Pharmacomm Ltd., Janssen Pharmaceuticals, Inc., Novo Nordisk Canada Inc., Pfizer Inc., Roche Diabetes Care. Other Relationship; Diabetes Canada. A. Klimek-Abercrombie: Employee; Novo Nordisk Canada Inc. G. Ng: Other Relationship; Novo Nordisk Canada Inc. A. Bunko: Other Relationship; Novo Nordisk Canada Inc. A.A. Kukaswadia: Other Relationship; Novo Nordisk. C.S. Neish: Other Relationship; Novo Nordisk Canada Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.